

Special Issue

Veterinary Vaccine Research at the Frontline of Vaccinology

Message from the Guest Editors

Here, we aim to present advances in veterinary vaccine research and development that hold promise to deliver new and exciting opportunities for further improvement of immunity against infectious challenges for humans and animals. Contributions may include how an understanding of immunological correlates of protection guides the design and formulation of vaccines and adjuvants, how mucosal immunity can be obtained through vaccination, advances in design of antigen presentation and delivery, e.g., via mRNA or virus replicon technology, and development of vaccines against parasites. Altogether, this collection will also emphasize how large animals can be used as relevant experimental models for advancing vaccine development for infections where no vaccines currently provide sufficient protection for humans.

Guest Editors

Prof. Gregers Jungersen

Statens Serum Institut, Veterinary Vaccine Research, Infectious Disease Immunology, Center for Vaccine Research, Artillerivej 5, 2300 Copenhagen S, Denmark

Dr. Gitte Erbs

Statens Serum Institut, Veterinary Vaccine Research, Infectious Disease Immunology, Center for Vaccine Research, Artillerivej 5, 2300 Copenhagen S, Denmark

Deadline for manuscript submissions

closed (30 September 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/76060

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).